Our Mission

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies.

Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.



A diagram showcasing Anwita's technology workflow.

Anwita’s core technology integrates structure-guided AccuKine cytokine evolution and AccuBody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile and great developmentability. Our unique product portfolio includes half-live extended Exenokines, immune cell- or tumor cell-targeting Mableukines, and bi-functional Duoleukins. These new generation of cytokines could serve as powerful novel immune therapies with a wide range of applications in treating patients with cancers and autoimmune diseases.


  1. Ye F. et al. A safe and highly potent anti-PD1-IL-2C fusion that decouples efficacy and toxicity of IL-2 therapy. https://anwitabio.com/aacr-poster.png
  2. Liu H. et al. An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade. Int Immunopharmacol. 2021 Dec;101(Pt A):108307. doi: 10.1016/j.intimp.2021.108307. Epub 2021 Nov 1. PMID: 34735918. https://pubmed.ncbi.nlm.nih.gov/34735918/
  3. Wu S. et al. The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. Front Cell Dev Biol. 2021 Nov 15;9:779865. doi: 10.3389/fcell.2021.779865. PMID: 34869384; PMCID: PMC8634682. https://pubmed.ncbi.nlm.nih.gov/34735918/






Lead ID

Lead OP

IND Enabling



Solid Tumors

JS014 is an Exenokine-21 molecule being developed as an IV infusion treatment for cancer patients, either alone or in combination with immune checkpoint inhibitors. The antitumor activities of JS014 have been demonstrated in multiple mouse tumor models, both as a superior single agent when compared to the unmodified rhIL-21 and as an effective combined agent potentiating the efficacy of immunotherapies. JS014 has recently received IND acceptance from the US FDA and China NMPA. Anwita plans to conduct a first-in-human Phase 1 clinical trial to evaluate the safety and efficacy of JS14 in cancer patients in Q1 2022. JS014 is partnered with Shanghai Junshi Biosciences for the Greater China territories.


Solid Tumors

TopAlliance Logo

Solid Tumors

RT003 is a systemically delivered Exenokine-2 molecule being developed to minimize the toxicity observed with recombinant IL-2 therapy while maximizing the clinical benefit as a monotherapy or in combination with immune checkpoint inhibitors in multiple tumor types. Key features of RT003 include preferential activation of the βγ-IL-2 receptor and extension of half-life for an improved systemic exposure. In preclinical studies, RT003 exhibits potent antitumor and PD activities with a favorable pharmacokinetic and tolerability profile. Pharmacological activity of RT003 is driven by the selective activation and expansion of effector T cells. RT003 is partnered with Shanghai Junshi Biosciences for the Greater China territories.


Solid Tumors

TopAlliance Logo

Solid Tumors

Mableukine-2PD1 is a targeted fusion protein comprised of an anti-PD1 antibody and an optimized IL-2. The IL-2 component is engineered to have significantly lower toxicity. The anti-PD1 antibody component of the fusion protein serves not only to block the interaction between PD1 and PD-L1 but also functions to direct the optimized IL-2 to the desired cell populations within the tumor microenvironment. Leveraging on the function of PD1 and IL-2 signaling pathway to selectively stimulate effector T cells, Mableukine-2PD1 exhibits excellent antitumor and pharmacodynamic activities with low systematic toxicities.

PD-1 and IL-2

Solid Tumors



IL-36 cytokines and their receptors are normally expressed at low levels but are markedly elevated during inflammation in several tissues including skin, lung, joints, and gut. The importance of proper IL-36 signaling has been demonstrated in several preclinical in vivo models of skin inflammation, lung inflammation, and inflammatory bowel disease. In the human setting, based on proof-of-concept clinical data, blockade of IL-36 signaling through inhibition of IL-36R could be an appealing therapeutic target for patients suffering from chronic and potentially life-threatening generalized pustular psoriasis. Anwita is developing a best-in-class IL-36R directed antibody-based therapeutic that exhibits exquisite potency and excellent developmentability profile.

IL-36 Receptor


Discovery Programs

Anwita applies our AccuKine cytokine evolution and AccuBody discovery platform to design, optimize, and validate new therapeutic candidates with improved pharmaceutical properties in immuno-oncology, autoimmune, and inflammatory disease areas.


Click or tap on any Program to read more about that project.

Our Leadership


Date: October 5th, 2022

Anwita Biosciences, Inc. Announces Multiple Poster Presentations Showcasing Its Three Cytokine-Based Therapeutics at 37th Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Press Release

Date: September 21st, 2022

Anwita Biosciences Announced Today Dosing of First Patient in Its Phase I Clinical Trial of JS014, a Half-life Extended IL-21, for the Treatment of Solid Tumors

Press Release

Date: March 15th, 2022

Anwita Biosciences, Inc. announces presentation on Mableukine-2PD1 at the 2022 annual American Association of Cancer Research (AACR) meeting.

Press Release

Date: October 29th, 2021

Anwita Biosciences, Inc. Announces Initiation of first-in-human Phase 1 clinical trial of Exenokine-21 for monotherapy and combination, earns $2.5 million milestone for IND acceptance from Partner Shanghai Junshi Biosciences

Press Release

Date: June 28th, 2021

Anwita Biosciences, Inc. Completes $18.5 Million Series B Financing to Advance Its Improved Cytokines (Exenokines) And Tumor Targeting Antibody Drug Conjugates

Press Release

Date: September 30th, 2020

Anwita Biosciences and Shanghai Junshi Biosciences entered into a new collaboration in which Junshi was granted the exclusive rights to Anwita's Exenokine-2, an improved IL-2 variant with extended half-life, in the Greater China territories.

Press Release

Date: June 24th, 2019

Strategic collaboration between Anwita Biosciences and Shanghai Junshi Biosciences whereby Junshi was granted the exclusive rights to develop and commercialize Anwita's Exenokine-21 program in the Greater China territories.

Press Release




Contribute to experimental planning, implementation, and data analysis; Independently design plasmid maps, primers and cloning strategies for antibodies and fusion proteins; Use ExpiCHO transient transfection and expression system to produce new proteins; Purify protein from ExpiCHO expression system and use analytical instrument including HPLC, AKTA to characterize protein quantity, quality and purity; Design mutations to change certain property of target protein, including receptor binding, stability and productivity; Use Octet Red96 instrument to perform binding assays and measure the dissociation constant; Perform cell based binding and functional screening assays to ID target specific antibody binders; Generate stable expression cell lines for cell based assays using pAS-puro vector and puromycin selection; Support antibody discovery team and perform phage display library construction and screening; Design and perform cell based assays, including cell surface staining, signaling assay and flow cytometry; Prepare reports and present in weekly group meeting.

Education and Experience

  • Master’s Degree (or foreign equivalent) in Molecular Biology, Biomedical Engineering, or related field
  • 2 years of experience in a research position in a biotechnology company. Position requires experience with:
    • molecular cloning
    • protein purification and characterization
    • cell culture


  • Competitive compensation
  • Stock options at all levels
  • 401(K) plan
  • Official holidays
  • Generous paid time off (PTO)
  • Sick days
  • Medical plan
  • Dental plan
  • Visional plan
  • Life insurance